We are the leading mid-market royalty acquisition company, based upon the number of transactions and aggregate value of capital deployed since 2016. We focus on growth assets and emerging companies driving innovation in the biopharmaceutical industry. We consider “mid-market” to comprise royalty acquisitions for transaction sizes between $20 million and $250 million. Our founders have been pioneers in the healthcare royalty and debt financing markets since 2001, and formed HCR in 2006 to build on their leadership in collaborating with inventors, academic institutions, small and mid-cap biotechnology companies and leading global pharmaceutical companies.
BMO Capital Markets Corp, Cowen and Company, LLC, Jefferies LLC, Raymond James and Associates, Inc, Stifel Nicolaus & Company, Incorporated, SVB Leerink LLC, Truist Securities, Inc
